We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Drug dealing

8 September 2010 By Alexander Smith

The pharma giant has picked Simon Dingemans as its new CFO. The move gives the Goldman dealmaker an escape from the antibanker backlash, and his expertise will be useful as the drugs industry consolidates. But bankersturnedcorporate executives have a mixed track record.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)